Cizzle Bio, Inc. released the CIZ1B Biomarker Blood Test, designed to provide an additional biomarker-based tool for lung cancer assessments.

Cizzle Bio, Inc. is at the forefront of biotechnological innovation, dedicated to revolutionizing lung cancer detection through our pioneering CIZ1B biomarker blood test. Our mission is to improve early-stage lung cancer diagnosis, enhancing patient outcomes with non-invasive, highly accurate diagnostic solutions. In collaboration with Cizzle Biotechnology PLC, we utilize patented technologies to offer an effective alternative to traditional screening methods. With a focus on continuous innovation, strategic partnerships, and patient-centered care, we aim to make early cancer detection accessible and reliable for all.